Exchange: NASDAQ·Updated 07:59 PM EDT

WVE News

News
all
press releases
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Zacks
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Zacks
More News
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.read more...
Benzinga
Wave Life Sciences Names Monika Vnuk Chief Business Officer
(RTTNews) - On Tuesday, Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company based in RNA medicines, announced the appointment of Monika Vnuk as the Chief Business Officer, and will join Waves executive team and lead business development, corporate development, a...
Nasdaq News: Markets
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -9.68% and -73.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
Wave Life Sciences (WVE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
Zacks
New Strong Buy Stocks for July 22nd
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
Zacks
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Zacks
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
Zacks

Advertisement|Remove ads.